|
|
|
|
| LEADER |
02677nam a2200349 u 4500 |
| 001 |
EB001872281 |
| 003 |
EBX01000000000000001035652 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190824 r ||| eng |
| 245 |
0 |
0 |
|a Pharmacoeconomic review report: Levodopa/Carbidopa (Duodopa) (Abbvie Corporation)
|h Elektronische Ressource
|b indication : for the treatment of patients with advanced levodopa-responsive Parkinson's disease
|
| 246 |
3 |
1 |
|a Levodopa/Carbidopa (Duodopa) (Abbvie Corporation)
|
| 246 |
3 |
1 |
|a Pharmacoeconomic review report for levodopa/carbidopa
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, September 2018
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Drug Therapy, Combination / economics
|
| 653 |
|
|
|a Parkinson Disease / drug therapy
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Carbidopa / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Antiparkinson Agents / economics
|
| 653 |
|
|
|a Levodopa / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Version: Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK539444
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a This review was undertaken at the request of the public drug plans participating in the Common Drug Review (CDR) process, which indicated that new evidence was available to support the clinical effectiveness of levodopa/carbidopa in the treatment of Parkinson disease (PD). CDR was asked to review levodopa/carbidopa intestinal gel (LCIG) as per the Health Canada indication, focusing on new clinical efficacy and safety data. The manufacturer of LCIG was invited to submit clinical and/or economic information, but was not obligated to do so. The manufacturer provided some relevant information, including previously published literature on clinical studies of LCIG, a clinical study report, and pricing information; it did not provide an economic model to support this review. Since no economic evaluation or model was submitted, this CDR Pharmacoeconomic Report focuses on an appraisal of published literature assessing the cost-effectiveness of LCIG in patients with advanced Parkinson disease compared with standard of care therapies (including apomorphine injections) and deep drain stimulation (DBS), with a focus on the new clinical evidence in which the participating plans expressed interest for this review
|